CLINICAL TRIALS PROFILE FOR NORDETTE-21
✉ Email this page to a colleague
All Clinical Trials for NORDETTE-21
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00685906 ↗ | AZD6140 Oral Contraceptive Interaction Study | Completed | AstraZeneca | Phase 1 | 2008-04-01 | The purpose of this study is to examine the effect of co-administration of AZD6140 and Nordette® on the blood levels of certain female hormones. |
| NCT01480778 ↗ | Evaluation of Ciclo 21® Effect (Levonorgestrel + Ethinyl Estradiol) Compared to Nordette®. | Completed | União Química Farmacêutica Nacional S.A. | Phase 3 | 2014-07-01 | Assessment of the pharmacodynamic profile of the drug Ciclo 21 ®, marketed by União Química Farmacêutica Nacional S / A, compared to the drug Nordette ® Laboratory Wyeth Pharmaceutical Ltda. Through the modulation of hormonal response (inhibition of the pituitary) evidenced by measurement serum LH and FSH for 28 days, as well as by the absence of follicle formation demonstrated by transvaginal ultrasound examinations |
| NCT01480778 ↗ | Evaluation of Ciclo 21® Effect (Levonorgestrel + Ethinyl Estradiol) Compared to Nordette®. | Completed | União Química Farmacêutica Nacional S/A | Phase 3 | 2014-07-01 | Assessment of the pharmacodynamic profile of the drug Ciclo 21 ®, marketed by União Química Farmacêutica Nacional S / A, compared to the drug Nordette ® Laboratory Wyeth Pharmaceutical Ltda. Through the modulation of hormonal response (inhibition of the pituitary) evidenced by measurement serum LH and FSH for 28 days, as well as by the absence of follicle formation demonstrated by transvaginal ultrasound examinations |
| NCT01480778 ↗ | Evaluation of Ciclo 21® Effect (Levonorgestrel + Ethinyl Estradiol) Compared to Nordette®. | Completed | Azidus Brasil | Phase 3 | 2014-07-01 | Assessment of the pharmacodynamic profile of the drug Ciclo 21 ®, marketed by União Química Farmacêutica Nacional S / A, compared to the drug Nordette ® Laboratory Wyeth Pharmaceutical Ltda. Through the modulation of hormonal response (inhibition of the pituitary) evidenced by measurement serum LH and FSH for 28 days, as well as by the absence of follicle formation demonstrated by transvaginal ultrasound examinations |
| NCT02404038 ↗ | A Study to Evaluate the Acceptability and Preference for Contraceptive Options as Proxy for HIV Prevention Methods | Unknown status | Desmond Tutu HIV Centre | N/A | 2015-07-01 | This study will enrol sexually active, healthy girls aged 16-17 to assess and compare the acceptability and preference for a monthly vaginal ring, bi-monthly injectable contraception or daily dose oral contraception, as proxy for female-controlled ARV-based HIV prevention methods. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NORDETTE-21
Condition Name
Clinical Trial Locations for NORDETTE-21
Trials by Country
Clinical Trial Progress for NORDETTE-21
Clinical Trial Phase
Clinical Trial Sponsors for NORDETTE-21
Sponsor Name
